- Home
- UTHR vs BAP Comparison
UTHR vs BAP Comparison
Compare UTHR & BAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UTHR
- BAP
- Stock Information
- Founded
- UTHR 1996
- BAP 1889
- Country
- UTHR United States
- BAP Peru
- Employees
- UTHR N/A
- BAP N/A
- Industry
- UTHR Biotechnology: Pharmaceutical Preparations
- BAP Major Banks
- Sector
- UTHR Health Care
- BAP Finance
- Exchange
- UTHR Nasdaq
- BAP Nasdaq
- Market Cap
- UTHR 14.4B
- BAP 14.5B
- IPO Year
- UTHR 1999
- BAP 1995
- Fundamental
- Price
- UTHR $295.22
- BAP $226.13
- Analyst Decision
- UTHR Buy
- BAP Hold
- Analyst Count
- UTHR 13
- BAP 4
- Target Price
- UTHR $386.15
- BAP $211.00
- AVG Volume (30 Days)
- UTHR 716.0K
- BAP 307.2K
- Earning Date
- UTHR 07-30-2025
- BAP 08-07-2025
- Dividend Yield
- UTHR N/A
- BAP 4.95%
- EPS Growth
- UTHR 18.86
- BAP 15.58
- EPS
- UTHR 25.10
- BAP 19.76
- Revenue
- UTHR $2,994,100,000.00
- BAP $5,114,481,827.00
- Revenue This Year
- UTHR $14.30
- BAP $25.40
- Revenue Next Year
- UTHR $6.32
- BAP $6.06
- P/E Ratio
- UTHR $11.76
- BAP $11.26
- Revenue Growth
- UTHR 19.84
- BAP 14.82
- 52 Week Low
- UTHR $266.98
- BAP $153.27
- 52 Week High
- UTHR $417.82
- BAP $226.85
- Technical
- Relative Strength Index (RSI)
- UTHR 49.75
- BAP 69.26
- Support Level
- UTHR $282.42
- BAP $218.59
- Resistance Level
- UTHR $293.77
- BAP $226.85
- Average True Range (ATR)
- UTHR 7.51
- BAP 4.40
- MACD
- UTHR 0.43
- BAP 0.12
- Stochastic Oscillator
- UTHR 98.55
- BAP 94.47
About UTHR United Therapeutics Corporation
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.
About BAP Credicorp Ltd.
Credicorp Ltd is a Peruvian financial services company. It operates in four business lines including Universal Banking, Insurance and Pensions, Microfinance, and Investment Management & Advisory. Its subsidiaries include Banco de Credito del Peru, Prima AFP, and Credicorp Capital.